Fovista pegpleranib: Completed Phase III enrollment

Ophthotech completed enrollment of about 622 patients in the last of 3 sham-controlled, double-blind, international Phase

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE